A detailed history of Los Angeles Capital Management LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 204,024 shares of CPRX stock, worth $4.42 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
204,024
Previous 200,282 1.87%
Holding current value
$4.42 Million
Previous $3.98 Million 6.93%
% of portfolio
0.02%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025

BUY
$19.73 - $23.93 $73,829 - $89,546
3,742 Added 1.87%
204,024 $4.26 Million
Q3 2024

Nov 04, 2024

BUY
$15.19 - $21.35 $1.87 Million - $2.63 Million
123,020 Added 159.22%
200,282 $3.98 Million
Q2 2024

Aug 05, 2024

SELL
$14.68 - $16.92 $55,123 - $63,534
-3,755 Reduced 4.63%
77,262 $1.2 Million
Q1 2024

Apr 05, 2024

BUY
$13.18 - $17.11 $462,169 - $599,979
35,066 Added 76.31%
81,017 $1.29 Million
Q4 2023

Feb 06, 2024

SELL
$11.78 - $17.29 $486,867 - $714,595
-41,330 Reduced 47.35%
45,951 $772,000
Q3 2023

Nov 06, 2023

SELL
$11.69 - $15.02 $11,000 - $14,133
-941 Reduced 1.07%
87,281 $1.02 Million
Q2 2023

Aug 03, 2023

SELL
$11.5 - $18.08 $252,436 - $396,874
-21,951 Reduced 19.92%
88,222 $1.19 Million
Q1 2023

May 04, 2023

SELL
$14.34 - $21.05 $250,405 - $367,575
-17,462 Reduced 13.68%
110,173 $1.83 Million
Q4 2022

Feb 06, 2023

SELL
$12.25 - $19.5 $170,360 - $271,186
-13,907 Reduced 9.83%
127,635 $2.37 Million
Q3 2022

Nov 02, 2022

SELL
$7.06 - $15.52 $1.6 Million - $3.51 Million
-226,092 Reduced 61.5%
141,542 $1.82 Million
Q2 2022

Aug 05, 2022

BUY
$6.23 - $8.57 $817,120 - $1.12 Million
131,159 Added 55.46%
367,634 $2.58 Million
Q1 2022

May 06, 2022

SELL
$5.31 - $8.31 $267,464 - $418,574
-50,370 Reduced 17.56%
236,475 $1.96 Million
Q4 2021

Feb 03, 2022

BUY
$5.21 - $7.45 $291,134 - $416,306
55,880 Added 24.19%
286,845 $1.94 Million
Q3 2021

Nov 08, 2021

BUY
$4.85 - $6.04 $277,323 - $345,367
57,180 Added 32.9%
230,965 $1.22 Million
Q2 2021

Aug 05, 2021

BUY
$4.29 - $6.05 $745,537 - $1.05 Million
173,785 New
173,785 $999,000
Q1 2021

May 05, 2021

SELL
$3.45 - $4.69 $1.25 Million - $1.7 Million
-362,065 Closed
0 $0
Q4 2020

Feb 04, 2021

SELL
$2.97 - $3.83 $78,170 - $100,805
-26,320 Reduced 6.78%
362,065 $1.21 Million
Q3 2020

Nov 02, 2020

SELL
$2.97 - $5.08 $256,860 - $439,343
-86,485 Reduced 18.21%
388,385 $1.15 Million
Q2 2020

Aug 05, 2020

BUY
$3.48 - $5.05 $556,330 - $807,318
159,865 Added 50.75%
474,870 $2.19 Million
Q1 2020

May 04, 2020

BUY
$2.61 - $5.21 $544,041 - $1.09 Million
208,445 Added 195.61%
315,005 $1.21 Million
Q4 2019

Feb 07, 2020

BUY
$3.67 - $5.7 $12,294 - $19,095
3,350 Added 3.25%
106,560 $400,000
Q3 2019

Nov 07, 2019

BUY
$3.89 - $7.43 $32,092 - $61,297
8,250 Added 8.69%
103,210 $548,000
Q2 2019

Jul 29, 2019

BUY
$2.7 - $6.11 $141,102 - $319,308
52,260 Added 122.39%
94,960 $365,000
Q4 2018

Feb 11, 2019

SELL
$1.92 - $3.62 $384 - $724
-200 Reduced 0.47%
42,700 $82,000
Q3 2018

Nov 05, 2018

BUY
$2.81 - $3.78 $72,891 - $98,053
25,940 Added 152.95%
42,900 $162,000
Q2 2018

Jul 31, 2018

BUY
$2.26 - $3.84 $38,329 - $65,126
16,960 New
16,960 $53,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.23B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.